Featured Research

from universities, journals, and other organizations

Improved outcomes for HPV-positive head and neck cancer with cetuximab and IMRT, study suggests

Date:
October 25, 2010
Source:
Georgetown University Medical Center
Summary:
Studies have shown higher survival rates for people with head and neck cancers that test positive for HPV when they are treated with systemic chemotherapy and radiation therapy. Now a new study suggests outcomes are also better when radiation therapy is combined with cetuximab, a targeted therapy.

Studies have shown higher survival rates for people with head and neck cancers that test positive for HPV when they are treated with systemic chemotherapy and radiation therapy. Now a new study suggests outcomes are also better when radiation therapy is combined with cetuximab, a targeted therapy.

Related Articles


The study, conducted at Georgetown Lombardi Comprehensive Cancer Center, analyzed tumors from sequentially treated patients between 2007 and 2009 with head and neck squamous cell carcinoma that were treated with cetuximab and intensity-modulated radiation therapy (IMRT). Of these patients, six had stage III disease and 14 had stage IVa disease. The median age was 63 (age ranged from 31 to 78). The patients received IMRT for seven to eight weeks (median dose was 72.0 Gy). Cetuximab was given for a median of seven cycles. Primary tumor sites included oral cavity (1), oropharynx (12), hypopharynx (1), larynx (5), and with one site unknown.

After a median follow up of 19 months, four patients had died and 12 patients had disease progression.

"We found a statistically significant higher progression free survival rates when comparing the outcomes of patients with HPV-positive tumors to those with HPV-negative tumors," explains Keith Unger, MD, lead author of the study.

One-year progression free survival rates were 100 percent for those with HPV-positive tumors and 31 percent for those who were HPV negative. Two year progression free survival rates were 60 percent for those with HPV compared to 23 percent for those with HPV negative tumors (p=0.05).

While not statistically significant, researchers observed a trend in improved overall survival. One-year overall survival rates were 100 percent for those with HPV-positive tumors versus 83 percent in HPV-negative tumors. Two-year survival rates were 100 percent for HPV-positive tumors compared to 71 percent for HPV negative tumors (p=0.12).

"We found no correlation between overall survival or progression free survival and stage, nodal status, primary site, or the duration of radiotherapy," Unger concludes.

The data is to be presented at the annual meeting of the American Society for Radiation Oncology, October 31st through November 4th in San Diego.


Story Source:

The above story is based on materials provided by Georgetown University Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Georgetown University Medical Center. "Improved outcomes for HPV-positive head and neck cancer with cetuximab and IMRT, study suggests." ScienceDaily. ScienceDaily, 25 October 2010. <www.sciencedaily.com/releases/2010/10/101025133743.htm>.
Georgetown University Medical Center. (2010, October 25). Improved outcomes for HPV-positive head and neck cancer with cetuximab and IMRT, study suggests. ScienceDaily. Retrieved March 6, 2015 from www.sciencedaily.com/releases/2010/10/101025133743.htm
Georgetown University Medical Center. "Improved outcomes for HPV-positive head and neck cancer with cetuximab and IMRT, study suggests." ScienceDaily. www.sciencedaily.com/releases/2010/10/101025133743.htm (accessed March 6, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, March 6, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Bupa Eyes India Healthcare Opportunities

Bupa Eyes India Healthcare Opportunities

Reuters - Business Video Online (Mar. 5, 2015) Bupa is hoping to expand in India&apos;s fast-growing health insurance market, once a rule change on foreign investment is implemented. The British private healthcare group&apos;s CEO tells Grace Pascoe why it&apos;s so keen on the new opportunity. Video provided by Reuters
Powered by NewsLook.com
Doctor in Your Pocket Is Getting Smarter

Doctor in Your Pocket Is Getting Smarter

Reuters - Business Video Online (Mar. 5, 2015) Mobile apps are turning smartphones into a personal doctors, with users able to measure heart rate, blood pressure and even blood sugar. But will it change our behaviour? Ivor Bennett reports from the Mobile World Congress in Barcelona. Video provided by Reuters
Powered by NewsLook.com
AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

Newsy (Mar. 5, 2015) AbbVie announced Wednesday it will buy cancer drugmaker Pharmacyclics in a $21 billion deal. Video provided by Newsy
Powered by NewsLook.com
Toddlers Drinking Coffee? Why You Shouldn't Share Your Joe

Toddlers Drinking Coffee? Why You Shouldn't Share Your Joe

Newsy (Mar. 5, 2015) A survey of Boston mothers and toddlers found that 15 percent of two-year-olds drink coffee and 2.5 percent of 1-year-olds. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins